Medtronic reported first quarter fiscal 2027 revenue of $9.8 billion, up 13.7% as reported and organically, and GAAP diluted EPS of $1.14 versus $0.81 a year earlier. The company raised its fiscal 2027 organic revenue growth guidance to 7.25% to 7.75% and its non-GAAP diluted EPS guidance to $5.94 to $6.00, both measures improving on the prior outlook.
Q1 revenue of $9.756 billion, up 13.7% as reported and organically; the extra fiscal week benefited organic growth by approximately $570 million, per the company
Q1 GAAP diluted EPS of $1.14, up 40.7%; non-GAAP diluted EPS of $1.45, up 15.1%
FY27 organic revenue growth guidance raised to 7.25% to 7.75% from 6.75% to 7.25%
FY27 non-GAAP diluted EPS guidance raised to $5.94 to $6.00 from $5.90 to $6.00
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Medtronic's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2026
$36.36B
+8.4%
$3.73
+3.3%
13.2%
FY2025
$33.54B
+3.6%
$3.61
+30.8%
13.9%
FY2024
$32.36B
+3.6%
$2.76
-2.1%
11.4%
FY2023
$31.23B
-1.4%
$2.82
-24.4%
12.0%
FY2022
$31.69B
+5.2%
$3.73
+40.2%
15.9%
Frequently asked questions
When is Medtronic's next earnings date?
Medtronic (MDT) is scheduled to report on Tuesday, November 17, 2026. Analysts expect EPS of $1.34.
What did Medtronic earn last quarter?
For the quarter ended Jul 2026, Medtronic reported diluted EPS of $1.14 (+40.7% year over year) on revenue of $9.76B (+13.7%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.